The Zhitong Finance App learned that on May 13, MSD (MRK.US) announced the latest progress of PD-1 antibody+tiGIT antibody combined adjuvant treatment for operable high-risk melanoma phase III clinical KeyVibe-010. Compared with the combination treatment group, the study is unlikely to reach the main end of RFS due to the higher discontinuation rate compared to the PD-1 single-drug treatment group (mainly due to immune-related side effects). Following the IDMC recommendation, MSD terminated the phase III clinical trial and revealed blindness. Patients in the combination treatment group can choose to continue to receive PD-1 monotherapy.
According to reports, this clinical setback is different from previous failures due to efficacy. The current application scenario is adjuvant treatment after surgery, and the safety requirements are higher than for advanced solid tumors. Despite this, the study showed that PD-1 plus TIGIT can lead to a stronger immune response while also leading to higher immune-related side effects.